Canada’s National Advisory Committee on Immunization has published guidance on the use of Nuvaxovid XBB.1.5, a recombinant protein subunit COVID-19 vaccine, in Canada, Novavax reported. “The recommendations state that Nuvaxovid XBB.1.5 can be used in unvaccinated or previously vaccinated individuals aged 12 years and older. This recommendation supports efforts to provide greater access to a non-mRNA protein-based COVID-19 vaccine option and could help achieve improved immunization rates. The vaccine has been distributed by the Public Health Agency of Canada across the regions, and provincial public health programs can advise on specific availabilities. Data from clinical trials continue to show broad neutralization responses to currently circulating forward-drift variants including JN.1 and JN.4 for our protein-based non-mRNA COVID-19 vaccine, while maintaining a favorable side effect profile. Peer-reviewed real-world effectiveness data is being published that shows the immune responses seen in our trials translates into COVID-19 prevention in the real world,” the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVAX:
- Novavax price target lowered to $19 from $35 at H.C. Wainwright
- Novavax call volume above normal and directionally bullish
- Novavax says CDC advisors in favor of added COVID vaccine dose for 65 and older
- Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Novavax sees FY24 revenue $800M-$1.000B, consensus $969.56M